• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Past Event

OHE Lunchtime Seminar: ‘Age, Utilities, and Self-Reported Health: Issues for HTA’

On Wednesday 18th May, Dr Patricia Cubi-Molla, Economist at the Office of Health Economics, will lead an OHE Lunchtime Seminar on the topic of ‘Age, utilities, and self-reported health: issues for HTA’. On Wednesday 18th May, Dr Patricia Cubi-Molla, Economist…

Date

17/05/16 11:00 pm

On Wednesday 18th May, Dr Patricia Cubi-Molla, Economist at the Office of Health Economics, will lead an OHE Lunchtime Seminar on the topic of ‘Age, utilities, and self-reported health: issues for HTA’.

On Wednesday 18th May, Dr Patricia Cubi-Molla, Economist at the Office of Health Economics, will lead an OHE Lunchtime Seminar on the topic of ‘Age, utilities, and self-reported health: issues for HTA’.

Occasionally, in health technology assessments (HTA), the situation arises that the central estimate of patients’ HRQoL available from clinical trials exceeds that of the general population with the same age and gender. It appears unclear how HTA agencies, such as NICE, should address such an issue – should the patients’ utility scores be used in the economic evaluation of cost effectiveness, or should they be downward-adjusted to reflect their poor health relative to that of general population without the condition? The way this issue is handled has important implications for HTA and health care resource prioritisation.

This problem appears to be more likely to occur in elderly populations. One possible explanation for the patient group mean score exceeding the general population mean score is that the existence of some older people with very poor health in the general population drags down the mean. There may also be differences in the way that the same underlying state of health is interpreted by individuals of different ages. It could also be due to people of different ages having different preferences regarding health, with an individual’s views about how good or bad  a given health state is reflecting their aspirations, fears and priorities, all of which may vary systematically with age. All this opens up the possibility that a technology may not be cost-effective on average but cost-effective for a sub-group whose preferences over health are more closely aligned to the benefits offered by the technology. The use of preference sub-groups can therefore increase overall health and improve efficiency by making the technology available only for the relevant sub-group, as long as that sub-group can easily be identified (such as one defined by age).

However, it is unclear whether any differences observed between age groups are driven by genuine differences in preferences or by artefacts of the technique used to elicit the preferences. Given the multitude of factors that could be driving differences in utilities, it is informative to examine the ways in which people’s valuations of hypothetical health states (e.g., using TTO) differ between methods, and from self-ratings of their own health (e.g., on the EQ VAS).

The aim of this research is to investigate several features which may explain the fact that a central estimate of HRQoL for a group of elderly patients can exceed that of the general population with the same age. Specifically, the seminar will address the following questions:

  • Can we find significant differences in the variation of self-reported HRQoL values around a central estimate, when comparing different age groups?
  • How do these differences (if any) depend on the central measure used (mean or median)?
  • How does age affect respondents’ HRQoL valuations of hypothetical EQ-5D health states?
  • What is the rationale for age-adjusting the utilities to be used in HTA? Is there a case for using utilities specific to age (or other relevant) sub-groups?

This piece of research is based on findings from a research study performed by OHE and Roche Products Ltd and funded by Roche Products Ltd. Views expressed in the seminar are those of the authors.

Patricia Cubi-Molla joined OHE in September 2015. Patricia’s main areas of research are: health-related quality of life measures, subjective well-being, cost-effectiveness thresholds, estimation of health-related outcomes, health policy evaluation, adaptation to health states, ordered choice models and theory of preferences.

Patricia obtained her PhD in Economics from the Quantitative Economics Doctorate (QED, University of Alicante) in 2009, after obtaining her BSc in Mathematics from the same university in 2002. Moving to the UK in 2009, she has been working as a Lecturer in Economics at City University London, where she has been actively involved in the Health Economics and Economic Evaluation in Health Care master programmes offered by the Department of Economics.

Further information can be obtain from Kerry Sheppard

Full invitation available here.

Related Events

Tekado
  • Past Event
  • Commissioned Webinar
  • August 2023

Partnerships for Health System Innovation and Improvement

Read more
Eco-conscious car journeying through forest landscape, Earth pla
  • Past Event
  • Annual Lecture
  • July 2023

OHE Annual Lecture 2023 | The ECO-nomics of Health in a Shifting Climate: Fostering Well-being, Sustainable Livelihoods, and a Greener Future

Read more
cape-town-2575437
  • Past Event
  • July 2023

OHE at IHEA 2023

Read more
sustainaibiity
  • Past Event
  • OHE Webinar
  • Sponsored Webinar
  • May 2023

Supporting Sustainability in the Era of Green Pharmaceuticals

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!